The news came through at 10am: three experimental Ebola vaccines are being fast-tracked into human trials. The urgency is palpable. This is not a drill. The World Health Organisation has activated its highest alert level, and for the first time in years, the word ‘pandemic’ is being whispered in corridors of power. But beyond the headlines and the press releases, there is a quiet, anxious hum on the streets. People are watching. They are remembering.
In 2014, when Ebola tore through West Africa, the world was caught off guard. The response was slow, fragmented. Over 11,000 people died. The virus exposed the brittle scaffolding of global health infrastructure, and the deep inequities that determine who lives and who dies. Now, with cases emerging in Uganda and the Democratic Republic of Congo, and a traveller in Europe showing symptoms, the stakes feel higher. The vaccines are here, but the trials are a gamble.
The three candidates are from Johnson & Johnson, Merck and a newer collaboration between Oxford University and the Serum Institute of India. Each uses a different viral vector, a different approach to sparking immunity. The trials will be accelerated, but safety cannot be compromised. Volunteers are stepping forward, knowing the risks. Some are driven by altruism, others by a desperate need to protect their families. One nurse in Kampala told me: “We have no choice. The virus doesn’t wait for paperwork.”
This is the human cost: the fear of the unknown, the trust placed in science, the long months of waiting for data. For those in affected regions, the vaccine is a fragile hope. For the rest of the world, it is a reminder that no border is secure. The cultural shift is already underway: we are moving from complacency to vigilance. Hand sanitiser is selling out again. Travel restrictions are being discussed. The memory of COVID-19 is fresh, and it has changed us. We are less naive about the promises of containment.
But there is also a darker undercurrent: the spectre of vaccine nationalism. Wealthy nations have already begun stockpiling doses, while poorer countries scramble for scraps. The trials, if successful, will produce millions of doses but not enough for everyone. Who decides who gets the jab first? The same old dynamics of power and privilege. It is a stark lesson in class dynamics on a global scale.
I spoke to Dr. Amina Yusuf, an epidemiologist in Nairobi. “We are racing against the virus, but also against ourselves,” she said. “The vaccines are our best shot, but only if we distribute them fairly. Otherwise, we will have a two-tiered world: the protected and the vulnerable.” Her words linger.
The trials will take months. In the meantime, communities are preparing. Schools are rehearsing closure protocols. Hospitals are drilling for surge patients. And in the quiet moments, people are talking. About what matters. About who they trust. About the fragility of normality. The vaccines represent a scientific triumph, but the real story is the human one: the courage of volunteers, the weight of waiting, the small kindnesses that emerge in crisis.
This is not just a medical story. It is a mirror held up to our society. Look closely. What do you see?
